Regulatory Reviewers In Europe Face Overtime And Cancelled Vacations Due To Submission Delays
EU national competent authorities are stressed about having to put up with an “unacceptably high workload” due to poor submission planning by drug companies when it comes to their EU filings. Poor predictability relating to submissions could also impact industry.